News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
326,413 Results
Type
Article (19523)
Company Profile (139)
Press Release (306751)
Section
Business (105147)
Career Advice (863)
Deals (18489)
Drug Delivery (89)
Drug Development (50605)
Employer Resources (79)
FDA (7630)
Job Trends (7710)
News (185427)
Policy (17286)
Tag
Academia (726)
Alliances (27663)
Alzheimer's disease (553)
Approvals (7593)
Artificial intelligence (75)
Bankruptcy (170)
Best Places to Work (5462)
Biosimilars (66)
Biotechnology (61)
Cancer (468)
Cardiovascular disease (50)
Career advice (701)
Cell therapy (67)
Clinical research (41533)
Collaboration (172)
Compensation (62)
COVID-19 (1068)
Data (480)
Diabetes (84)
Diagnostics (1706)
Drug pricing (90)
Earnings (37940)
Employer resources (73)
Events (47325)
Executive appointments (164)
FDA (7853)
Funding (127)
Gene therapy (82)
GLP-1 (470)
Government (1791)
Healthcare (5846)
Infectious disease (1112)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7280)
Job creations (2428)
Job search strategy (644)
Layoffs (249)
Legal (4074)
Lung cancer (89)
Manufacturing (110)
Medical device (1944)
Medtech (1947)
Mergers & acquisitions (11218)
Metabolic disorders (300)
Neuroscience (700)
NextGen Class of 2024 (2346)
Non-profit (900)
Northern California (557)
Obesity (197)
Opinion (172)
Patents (66)
People (32813)
Pharmaceutical (75)
Phase I (12926)
Phase II (17578)
Phase III (14167)
Pipeline (141)
Podcasts (53)
Policy (65)
Postmarket research (1609)
Preclinical (4537)
Radiopharmaceuticals (154)
Rare diseases (121)
Real estate (3164)
Regulatory (12079)
Research institute (815)
Resumes & cover letters (138)
Southern California (519)
Startups (2004)
United States (5286)
Vaccines (204)
Weight loss (177)
Date
Today (130)
Last 7 days (402)
Last 30 days (1479)
Last 365 days (17948)
2024 (15297)
2023 (19637)
2022 (25870)
2021 (26648)
2020 (24874)
2019 (20061)
2018 (15587)
2017 (17254)
2016 (16204)
2015 (18803)
2014 (14789)
2013 (12555)
2012 (13483)
2011 (13817)
2010 (12738)
Location
Africa (406)
Arizona (49)
Asia (24394)
Australia (3137)
California (1254)
Canada (678)
China (123)
Colorado (52)
Connecticut (50)
Europe (50298)
Florida (168)
Illinois (125)
Indiana (108)
Kansas (55)
Maryland (202)
Massachusetts (1089)
Minnesota (76)
New Jersey (502)
New York (380)
North Carolina (341)
Northern California (557)
Ohio (60)
Pennsylvania (323)
South America (603)
Southern California (519)
Texas (158)
Washington State (125)
326,413 Results for "meiji seika pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 13, 2024
·
7 min read
Drug Development
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
Meiji Seika Pharma Co., Ltd. announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis conducted in the United States and Canada were presented on 12 October at the European Association of Dermatology and Venereology Congress 2023 held in Berlin.
October 13, 2023
·
2 min read
Drug Development
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. announced that ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index, in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
August 9, 2023
·
1 min read
A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
Meiji Seika Pharma Co., Ltd. and the Foundation for Biomedical Research and Innovation at Kobe announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” conducted at the FBRI’s Dept. of Immunology, Institute of Biomedical Research and Innovation.
January 16, 2023
·
2 min read
Drug Development
Meiji Seika Pharma: First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. announced that the first patient was dosed in Phase II clinical trial of ME3183, a selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis in the United States and Canada.
April 7, 2022
·
1 min read
Business
Meiji Seika Pharma Sets up a New Subsidiary in the US
Meiji Seika Pharma Co., Ltd. announces the starting of operation of its US subsidiary, Meiji Pharma USA Inc., for expanding activities in the US with its initial focus on facilitating clinical development.
January 4, 2021
·
1 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Drug Development
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
Meiji Seika Pharma Co., Ltd. announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States.
May 20, 2021
·
2 min read
Drug Development
CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
Meiji Seika Pharma Co., Ltd. announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States.
May 21, 2021
·
2 min read
1 of 32,642
Next